FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $216,208 | -88.3% | 101,985 | -73.8% | 0.00% | -85.7% |
| Q2 2023 | $1,849,508 | -0.0% | 388,552 | +19.7% | 0.01% | -74.1% |
| Q1 2023 | $1,849,690 | +292.5% | 324,507 | +594.8% | 0.03% | +200.0% |
| Q4 2022 | $471,253 | +12.5% | 46,705 | +149.8% | 0.01% | +12.5% |
| Q3 2022 | $419,000 | -60.2% | 18,700 | -31.2% | 0.01% | -71.4% |
| Q1 2022 | $1,054,000 | +294.8% | 27,175 | +503.2% | 0.03% | +250.0% |
| Q3 2021 | $267,000 | -65.1% | 4,505 | -46.4% | 0.01% | -84.3% |
| Q4 2020 | $765,000 | – | 8,410 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |